A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

NCT07219420 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Palmoplantar Pustulosis

Interventions

DRUG: Bimekizumab
DRUG: Placebo

Sponsor

UCB Biopharma SRL